Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
about
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRomidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.Gamma-delta t-cell lymphomas.Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.Impact of ABCB1 allelic variants on QTc interval prolongation.A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.Interpreting clinical assays for histone deacetylase inhibitors.Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaComparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostereRomidepsin in the treatment of cutaneous T-cell lymphoma.Cell death signaling and anticancer therapyElevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell functionEmerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.New drug therapies in peripheral T-cell lymphoma.Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.Toxicological and metabolic considerations for histone deacetylase inhibitors.Romidepsin for peripheral T-cell lymphoma.The discovery and development of romidepsin for the treatment of T-cell lymphoma.Pharmacogenomics and histone deacetylase inhibitors.Romidepsin for cutaneous T-cell lymphoma.HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.
P2860
Q33386623-86BDFA35-3BFD-40BB-85F9-99529EBA2B15Q33390876-C4D1726C-3268-4509-BD53-A539EE996F1EQ33394324-BAC0E977-981A-4E16-86FF-B0DAC27FB0BEQ33417290-554F01E1-AA91-4763-B5C9-113DB401E6DDQ33423486-4889E382-B2C2-4F5D-9B0F-4CFB7E5B2C8DQ33443153-8B4AAC2A-B76E-4169-B4F7-707CE544A467Q34441748-EB303E4F-B022-4FC8-B471-1A6F151FBA32Q34729026-6671B9F8-4737-4546-8FE6-C57FB39ACC33Q34781769-DA70B8DB-6782-47FB-9219-0F31B51E1F2CQ34977381-843676EB-F1CC-4A4D-8003-CFA884DAE0A6Q35003657-F12B0785-D84D-42D8-AEA9-FEBCF30DF1EFQ35186682-5A3EDA99-308A-461E-857C-7B4F03025A0BQ35202369-409346B7-3F5E-4EB8-9397-F4809780A617Q35683831-CEBFF8AE-ADE0-4F42-9B34-E6D8C59AFB7EQ35972102-70968A66-8504-4AA8-A5DC-67C55D7567E4Q36644877-0CCBE9B3-5D0B-43FC-BBA5-E34A9180B76EQ37144949-38AC2787-5441-4C9E-A760-009F73B5B4FBQ37809875-A694D2CA-81CC-47B7-8AA8-AC46D2049870Q37854715-1BF13A66-02B6-42E3-A06F-838ED20D852DQ38042561-E087CFE4-A742-458C-8999-756CFD2D75B1Q38071321-F9500458-2111-4316-9D3B-8F1B706AAE58Q38132813-EE2E1142-F245-45CF-8A27-24F473EE002CQ38713744-03B57420-9BCE-4C0E-9964-E8FD10D2EBCEQ38987332-C847DBED-80E2-4194-AE9B-68B5994E28D0Q39303355-CF4038A4-D755-44F0-8896-825F8D62C638Q40515496-32EFCB17-A065-451C-86CD-5A41479EFD87Q41573605-8B8A23A2-1771-42C1-9747-116E919719B6Q47951320-7603162C-2399-4786-B55A-124FD52B0D92
P2860
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population pharmacokinetics of ...... sed peripheral T-cell lymphoma
@en
Population pharmacokinetics of ...... ed peripheral T-cell lymphoma.
@nl
type
label
Population pharmacokinetics of ...... sed peripheral T-cell lymphoma
@en
Population pharmacokinetics of ...... ed peripheral T-cell lymphoma.
@nl
prefLabel
Population pharmacokinetics of ...... sed peripheral T-cell lymphoma
@en
Population pharmacokinetics of ...... ed peripheral T-cell lymphoma.
@nl
P2093
P2860
P1476
Population pharmacokinetics of ...... sed peripheral T-cell lymphoma
@en
P2093
Caitlin E Baum
Douglas K Price
Erin R Gardner
Richard L Piekarz
Robin Frye
Sandra B Ockers
Sukyung Woo
Susan E Bates
Tristan M Sissung
William D Figg
P2860
P304
P356
10.1158/1078-0432.CCR-08-1215
P407
P577
2009-02-01T00:00:00Z